Cargando…
Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy
This study was designed to explore if antiviral treatment influences the performance of serum alpha‐fetoprotein (AFP) for hepatocellular carcinoma (HCC) among the high‐risk chronic HBV‐infected patients. A total of 5936 patients who had evidence of chronic HBV infection were enrolled from four indep...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756791/ https://www.ncbi.nlm.nih.gov/pubmed/32852885 http://dx.doi.org/10.1111/jvh.13388 |
_version_ | 1783626618427670528 |
---|---|
author | Qian, Xiangjun Liu, Shuhong Long, Huiling Zhang, Siyu Yan, Xiaotong Yao, Mingjie Zhou, Jiyuan Gong, Jiao Wang, Jianwen Wen, Xiajie Zhou, Tao Zhai, Xiangwei Xu, Qiang Zhang, Ting Chen, Xiangmei Hu, Guoxin Wang, Jie Gao, Zhiliang Nan, Yuemin Chen, Junhui Hu, Bo Zhao, Jingmin Lu, Fengmin |
author_facet | Qian, Xiangjun Liu, Shuhong Long, Huiling Zhang, Siyu Yan, Xiaotong Yao, Mingjie Zhou, Jiyuan Gong, Jiao Wang, Jianwen Wen, Xiajie Zhou, Tao Zhai, Xiangwei Xu, Qiang Zhang, Ting Chen, Xiangmei Hu, Guoxin Wang, Jie Gao, Zhiliang Nan, Yuemin Chen, Junhui Hu, Bo Zhao, Jingmin Lu, Fengmin |
author_sort | Qian, Xiangjun |
collection | PubMed |
description | This study was designed to explore if antiviral treatment influences the performance of serum alpha‐fetoprotein (AFP) for hepatocellular carcinoma (HCC) among the high‐risk chronic HBV‐infected patients. A total of 5936 patients who had evidence of chronic HBV infection were enrolled from four independent centres in this retrospective study, including 1721 chronic hepatitis B (CHB), 2286 liver cirrhosis (LC), 798 HCC within Milan criteria and 1131 HCC beyond Milan criteria patients. Stratified by whether they received treatment or not, the patients were further divided into antiviral and non‐antiviral groups. Then, the performance of AFP for discriminating HCC was evaluated. Patients receiving antivirals had significantly lower median levels of AFP compared with the non‐antiviral patients (P < .001), and there were significantly less patients with abnormal AFP levels in antiviral groups (P < .001). Antiviral therapy improved the AUROCs of AFP for discriminating HCC within Milan criteria. When setting the cut‐off values at 20 ng/mL and 100 ng/mL as surveillance and confirmatory tests respectively for HCC among patients receiving antiviral treatment, AFP exhibited a significantly higher sensitivity than those of 200 ng/mL and 400 ng/mL, which are currently recommended by some guidelines, without compromising specificity. Further analysis in antiviral patients revealed that serum AFP had better performance for discriminating HCC within Milan criteria in ALT ≤ 1ULN patients than that in ALT > 1ULN patients. In conclusion, in the era of antiviral therapy, serum AFP's surveillance performance was substantially improved for HCC within Milan criteria among the high‐risk population of CHB and LC patients. |
format | Online Article Text |
id | pubmed-7756791 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77567912020-12-28 Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy Qian, Xiangjun Liu, Shuhong Long, Huiling Zhang, Siyu Yan, Xiaotong Yao, Mingjie Zhou, Jiyuan Gong, Jiao Wang, Jianwen Wen, Xiajie Zhou, Tao Zhai, Xiangwei Xu, Qiang Zhang, Ting Chen, Xiangmei Hu, Guoxin Wang, Jie Gao, Zhiliang Nan, Yuemin Chen, Junhui Hu, Bo Zhao, Jingmin Lu, Fengmin J Viral Hepat Original Articles This study was designed to explore if antiviral treatment influences the performance of serum alpha‐fetoprotein (AFP) for hepatocellular carcinoma (HCC) among the high‐risk chronic HBV‐infected patients. A total of 5936 patients who had evidence of chronic HBV infection were enrolled from four independent centres in this retrospective study, including 1721 chronic hepatitis B (CHB), 2286 liver cirrhosis (LC), 798 HCC within Milan criteria and 1131 HCC beyond Milan criteria patients. Stratified by whether they received treatment or not, the patients were further divided into antiviral and non‐antiviral groups. Then, the performance of AFP for discriminating HCC was evaluated. Patients receiving antivirals had significantly lower median levels of AFP compared with the non‐antiviral patients (P < .001), and there were significantly less patients with abnormal AFP levels in antiviral groups (P < .001). Antiviral therapy improved the AUROCs of AFP for discriminating HCC within Milan criteria. When setting the cut‐off values at 20 ng/mL and 100 ng/mL as surveillance and confirmatory tests respectively for HCC among patients receiving antiviral treatment, AFP exhibited a significantly higher sensitivity than those of 200 ng/mL and 400 ng/mL, which are currently recommended by some guidelines, without compromising specificity. Further analysis in antiviral patients revealed that serum AFP had better performance for discriminating HCC within Milan criteria in ALT ≤ 1ULN patients than that in ALT > 1ULN patients. In conclusion, in the era of antiviral therapy, serum AFP's surveillance performance was substantially improved for HCC within Milan criteria among the high‐risk population of CHB and LC patients. John Wiley and Sons Inc. 2020-09-22 2021-01 /pmc/articles/PMC7756791/ /pubmed/32852885 http://dx.doi.org/10.1111/jvh.13388 Text en © 2020 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Qian, Xiangjun Liu, Shuhong Long, Huiling Zhang, Siyu Yan, Xiaotong Yao, Mingjie Zhou, Jiyuan Gong, Jiao Wang, Jianwen Wen, Xiajie Zhou, Tao Zhai, Xiangwei Xu, Qiang Zhang, Ting Chen, Xiangmei Hu, Guoxin Wang, Jie Gao, Zhiliang Nan, Yuemin Chen, Junhui Hu, Bo Zhao, Jingmin Lu, Fengmin Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title | Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title_full | Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title_fullStr | Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title_full_unstemmed | Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title_short | Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy |
title_sort | reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of hbv‐related hepatocellular carcinoma in the era of antiviral therapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7756791/ https://www.ncbi.nlm.nih.gov/pubmed/32852885 http://dx.doi.org/10.1111/jvh.13388 |
work_keys_str_mv | AT qianxiangjun reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT liushuhong reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT longhuiling reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhangsiyu reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT yanxiaotong reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT yaomingjie reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhoujiyuan reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT gongjiao reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT wangjianwen reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT wenxiajie reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhoutao reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhaixiangwei reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT xuqiang reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhangting reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT chenxiangmei reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT huguoxin reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT wangjie reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT gaozhiliang reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT nanyuemin reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT chenjunhui reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT hubo reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT zhaojingmin reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy AT lufengmin reappraisalofthediagnosticvalueofalphafetoproteinforsurveillanceofhbvrelatedhepatocellularcarcinomaintheeraofantiviraltherapy |